Sign in
4/A

Changes in Ownership

GYRE THERAPEUTICS, INC. Filed Acc 0001209191-21-028356

Options or other derivatives

  • Chief Financial Officer acquired 54,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Musil Clinton Chief Financial Officer 2021-02-08 Grant or award · Stock Option (Right to Buy) +54,000 54,000 D: show line 1 in the form
Loading xslF345X03/doc4a.xml…